StockComparison Logo
vs

SLRN vs ANTX

Comparison between Acelyrin Inc (SLRN, Company) and AN2 Therapeutics Inc (ANTX, Company).

Both SLRN and ANTX are from the Healthcare sector.

SLRN vs ANTX - Performance Comparison

Key Characteristics

Financial metrics and valuation ratios

Market Cap
Winner
SLRN
$229M
ANTX
$228M
Max Drawdown
Winner
SLRN
93.44%
ANTX
95.60%
Sharpe Ratio
SLRN
-1.13
Winner
ANTX
1.84
5Y Beta
Winner
SLRN
0.38
ANTX
0.62
Industry
SLRN
Biotechnology
ANTX
Biotechnology
P/E Ratio
SLRN
-0.84
Winner
ANTX
-5.40
Debt to Equity
SLRN
0.00%
ANTX
0.00%
Free Cash Flow Yield
SLRN
N/A
ANTX
-13.46%
P/B Ratio
SLRN
0.56
ANTX
N/A

SLRN vs ANTX - Historical Returns

Returns include dividend reinvestment.

1M
SLRN
+0.00%
Winner
ANTX
+31.43%
3M
SLRN
+0.00%
Winner
ANTX
+38.75%
6M
SLRN
+0.00%
Winner
ANTX
+464.15%
1Y
SLRN
+0.00%
Winner
ANTX
+469.52%
5Y(CAGR)
SLRN
N/A
ANTX
-19.40%
Max(CAGR)
SLRN
-46.84%
Winner
ANTX
-19.40%

SLRN vs ANTX - Annual Returns (2022 - 2026)

Returns include dividend reinvestment.

YearSLRNANTX
2026+0.00%+438.74%
2025-31.21%-17.99%
2024-60.45%-93.05%
2023-58.56%+110.80%
2022N/A-38.12%

SLRN vs ANTX Drawdown Comparison

The maximum drawdown for SLRN was -93.44%, occurring on Feb 4, 2025. This drawdown has not yet recovered.

The maximum drawdown for ANTX was -95.60%, occurring on Aug 16, 2024. This drawdown has not yet recovered.

The current SLRN drawdown is -92.12%. The current ANTX drawdown is -73.17%.

RankSLRNANTX
#1-93.44%
Aug 22, 2023 - Feb 4, 2025
-95.60%
Aug 15, 2022 - Aug 16, 2024
#2-33.11%
May 11, 2023 - Jul 28, 2023
-59.56%
May 6, 2022 - Aug 12, 2022
#3-5.52%
Jul 28, 2023 - Aug 9, 2023
-13.49%
Apr 1, 2022 - Apr 28, 2022
#4-2.35%
Aug 9, 2023 - Aug 15, 2023
-2.60%
Mar 25, 2022 - Apr 1, 2022
#5-1.59%
Aug 15, 2023 - Aug 21, 2023
-1.82%
Apr 28, 2022 - May 2, 2022
#6N/A-1.31%
May 2, 2022 - May 4, 2022

Correlation

Correlation between SLRN and ANTX is 0.46 which considered as a weak positive correlation - the stocks show a slight tendency to move together.

0.46
-101

Select Stocks to Compare